AP-303 is under clinical development by Shanghai Alebund Pharmaceuticals and currently in Phase I for Diabetic Nephropathy. According to GlobalData, Phase I drugs for Diabetic Nephropathy have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AP-303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AP-303 overview

AP-303 is under development for the treatment of diabetic kidney disease (DKD).The drug candidate targets on renal hemodynamics and attenuates glomerular hyperfiltration. It is administered through oral route.

Shanghai Alebund Pharmaceuticals overview

Shanghai Alebund Pharmaceuticals., is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. The company is headquartered Hong Kong Special Administrative Region of

For a complete picture of AP-303’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.